Open Access

Effect of RAD51C expression on the chemosensitivity of Eμ-Myc p19Arf‑/‑ cells and its clinical significance in breast cancer

  • Authors:
    • Shao‑Guang Liao
    • Lu Liu
    • Ya‑Jie Wang
  • View Affiliations

  • Published online on: February 28, 2018     https://doi.org/10.3892/ol.2018.8133
  • Pages: 6107-6114
  • Copyright: © Liao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the chemosensitivity to anti‑cancer drugs of RAD51 paralog C (RAD51C)-deficient Eμ-Myc p19Arf‑/‑ cells, to detect the expression of RAD51C in breast cancer tissues by immunohistochemistry (IHC), and to explore their association with clinicopathological factors. Eμ‑Myc p19Arf‑/‑ cells were stably transfected with retroviruses co‑expressing short hairpin‑RNA against RAD51C and green fluorescent protein (GFP). A single‑cell flow cytometry‑based GFP competition assay was used to assess the change in sensitivity to anti‑cancer drugs. GFP‑negative cells in the same population served as an internal control. In total, tissue samples from 213 cases of breast cancer and 99 adjacent non‑cancerous tissue samples were collected to construct tissue microarrays. IHC was used to detect the expression of RAD51C protein. Relevant clinical information was collected for a correlation analysis. Transfection of RAD51C‑shRNA was demonstrated to effectively reduce the RAD51C protein expression in the Eμ‑Myc p19Arf‑/‑ cells. The sensitivities of the cells to three drugs, camptothecin, cisplatin and olaparib, significantly increased following RAD51C gene knockdown. In breast cancer tissue, RAD51C expression was significantly higher in the Erb‑B2 receptor tyrosine kinase 2 overexpression group. The overall survival time of the patients with RAD51C‑negative expression was longer than that of patients with RAD51C‑positive expression. RAD51C expression was an independent prognostic factor for survival of breast cancer patients. In summary, the results indicate that silencing of RAD51C may represent a potential therapeutic strategy for malignant tumors, and that measuring RAD51C expression by IHC may have prognostic value for breast cancer patients.
View Figures
View References

Related Articles

Journal Cover

May-2018
Volume 15 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liao SG, Liu L and Wang YJ: Effect of RAD51C expression on the chemosensitivity of Eμ-Myc p19Arf‑/‑ cells and its clinical significance in breast cancer. Oncol Lett 15: 6107-6114, 2018.
APA
Liao, S., Liu, L., & Wang, Y. (2018). Effect of RAD51C expression on the chemosensitivity of Eμ-Myc p19Arf‑/‑ cells and its clinical significance in breast cancer. Oncology Letters, 15, 6107-6114. https://doi.org/10.3892/ol.2018.8133
MLA
Liao, S., Liu, L., Wang, Y."Effect of RAD51C expression on the chemosensitivity of Eμ-Myc p19Arf‑/‑ cells and its clinical significance in breast cancer". Oncology Letters 15.5 (2018): 6107-6114.
Chicago
Liao, S., Liu, L., Wang, Y."Effect of RAD51C expression on the chemosensitivity of Eμ-Myc p19Arf‑/‑ cells and its clinical significance in breast cancer". Oncology Letters 15, no. 5 (2018): 6107-6114. https://doi.org/10.3892/ol.2018.8133